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Abstract 
Dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) and cdc2-like kinases 
(CLKs) are implicated in the onset and progression of Down syndrome (DS) and Alzheimer’s 
disease (AD). DYRK1A has emerged as a possible link between amyloid- (A) and Tau, the 
major pathological proteins in AD. We here assessed the neuroprotective potential of a novel 
inhibitor of DYRKs/CLKs. The Leucettine L41, acting preferentially on DYRK1A, was tested 
in A25-35-treated mice, a nontransgenic model of AD-like toxicity. We co-injected 
intracerebroventricularly oligomeric A25-35 peptide and L41 in Swiss male mice. After 7 days, 
they were submitted to behavioral tests addressing spatial and non-spatial, short- and long-
term memories. The oxidative stress, apoptotic markers, kinases involved in Tau 
phosphorylation, and synaptic integrity were analyzed by western blot and ELISA in the 
hippocampus. L41, tested at 0.4, 1.2, 4 µg, prevented the A25-35-induced memory deficits in 
the Y-maze, passive avoidance and water-maze tests, with the most active dose being 4 µg. 
The inhibitor prevented the A25-35-induced oxidative stress, as revealed by measures of lipid 
peroxidation levels and reactive oxygen species accumulation, and abolished A25-35-induced 
expression of pro-apoptotic markers. L41 prevented the A25-35-induced decrease of AKT 
activation and increase of glycogen synthase kinase-3 (GSK-3) activation, resulting in a 
decrease of Tau phosphorylation. Finally, L41 restored A25-35-reduced levels of synaptic 
markers. The novel DYRK1A-preferential inhibitor L41 therefore prevented A25-35-induced 
memory impairments and neurotoxicity in the mouse hippocampus. These in vivo data 
highlighted particularly DYRK1A as a major kinase involved in A pathology and suggested 
therapeutic developments for DYRK1A inhibitors in AD. 
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1. Introduction 
 
Alzheimer’s disease (AD), the most prevalent dementia in the elderly, is characterized by a 
progressive decline in executive and cognitive functions (Selkoe, 2002). The pathological 
diagnosis of this age-related disorder depends on the presence of both amyloid- (A) 
plaques and intraneuronal tangles, consisting of hyper-phosphorylated Tau proteins (Selkoe, 
2002). The A hypothesis of AD pathophysiology posits that A induced the formation of 
Tau-containing neurofibrillary tangles and neuronal death, which contribute to progressively 
worsen cognitive abilities. Indeed, amyloid deposition is one of the processes that trigger the 
cascade of molecular events leading to neurofibrillary degeneration. Several kinases, mainly 
glycogen synthase kinase-3 (GSK-3) and cyclin-dependent kinase 5 (CDK-5), are closely 
linked to AD neuropathology and are a possible link between A and Tau (Flaherty et al., 
2000; Iqbal et al., 2014). 
  Pre-phosphorylation of Tau by CDK-5 stimulates both the rate and extent of a 
subsequent phosphorylation catalyzed by GSK-3 (Sengupta et al., 1997). In addition to Tau 
phosphorylation, GSK-3 and CDK-5 regulate A generation through phosphorylation of the 
cytoplasmic domain of APP (Aplin et al., 1996; Iijima et al., 2000 and presenilin-1 (PS1) 
(Tesco and Tanzi, 2000; Lau et al., 2002). Despite these major roles in AD, inhibitors 
targeting these kinases have adverse effects in control group or depending on the AD 
hallmarks studied (Ryder et al., 2003; Hu et al., 2009). Considering these adverse effects 
and their major constitutive functions, these kinases may not be appropriate therapeutic 
targets for AD. Targeting other kinase with greater central and lesser peripheral function 
should be a better alternative. 
 The dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) has 
emerged as a kinase potentially involved in AD etiology. The first prima-facie evidence 
relates to the fact that DYRK1A gene is located on the chromosome 21, as the APP gene, a 
localization that supports DYRK1A implication in Down syndrome (DS) (Song et al., 1996; 
Kimura et al., 2007). Of great interest, DS subjects invariably develop AD at ages that are not 
usual in sporadic AD (de la Torre and Dierssen, 2012). In addition, DYRK1A mRNA 
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expression was elevated in the hippocampus of AD patients (Kimura et al., 2007) and 
DYRK1A immunoreactivity was increased in the frontal and entorhinal cortex and in the 
hippocampus of AD patients (Ferrer et al., 2005). Moreover, DYRK1A phosphorylated Tau 
on 11 phosphorylation sites, which are phosphorylated in AD, notably at Thr212, Ser202, Thr205 
and Thr231 (Woods et al., 2001; Liu et al., 2008). As observed for major kinases involved in 
AD, DYRK1A can also phosphorylate APP (Ryoo et al., 2008) and PS1 (Ryu et al., 2010). 
Therefore, DYRK1A acts as a major kinase linking A and Tau and contributing to apoptotic 
processes in AD. However, several studies also showed that DYRK1A can directly regulate 
cell death. For instance, Dyrk1A is coupled to JNK1 activation, and directly interacts with 
apoptosis signal-regulating kinase 1 (ASK1) (Choi and Chung, 2011). Additionally in the 
Ts65Dn mouse model of DS, triplication of DYRK1A provoked retinal structural and 
functional alterations resulting in apoptosis (Laguna et al., 2013). The role of DYRK1A in AD 
related apoptosis must therefore be addressed. 
 The aim of this study was to determine whether a Dyrk1A preferential kinase inhibitor 
could be neuroprotective in a mouse model of amyloid toxicity. L41, a member of the 
Leucettine family of low molecular weight inhibitors, is derived from the marine sponge 
alkaloid Leucettamine B (Debdab et al., 2011; Tahtouh et al., 2012). L41 is a potent inhibitor 
of DYRK and CLK kinases, which acts preferentially on DYRK1A. The two major DYRK1A 
preferential inhibitors are epigallocatechin-3-gallate (EGCG; IC50 = 0.33 µM) and harmine, 
which act also on other kinases (Adayev et al., 2011; Tahtouh et al., 2012). Comparatively to 
EGCG, harmine (IC50 = 34-85 nM) and L41 (IC50 = 10-60 nM) induce enhanced inhibition 
rates for all isoforms of DYRK1A. L41 also inhibits DYRK1B (IC50 = 44 nM), DYRK2 (IC50 = 
73 nM), CLK1 (IC50 = 71 nM), CLK4 (IC50 = 64 nM) and GSK-3/ (IC50 =210-410 nM) 
(Tahtouh et al., 2012). However, among these L41 kinase targets, DYRK1A is the only one 
target of L41 identified in mouse brain by affinity chromatography approaches (Tahtouh et 
al., 2012; Burgy et al., 2013). In addition, identification of affinity chromatography purified L41 
targets from various mouse tissues has revealed that expression pattern of it targets varies 
considerably from one organ to another, with the highest DYRK1A expression observed in 
brain (Tahtouh et al., 2012; Burgy et al., 2013).  
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 In the present study, we used a rapid model of A toxicity, consisting in 
intracerebroventricular (i.c.v.) injection of the A25-35 peptide (Maurice et al., 1996; Kaminsky 
et al., 2010) in oligomeric species (Zussy et al., 2013). A25-35 injection in mice and rats 
allows to assess the therapeutic potential of new compounds. It mimics the major hallmarks 
observed in AD, including memory deficits, oxidative stress, astrogliosis and microgliosis, 
neuroinflammation, pro-apoptotic caspases activity and loss of hippocampal and cholinergic 
neurons (Maurice et al., 1996; Kaminsky et al., 2010; Zussy et al., 2011). More particularly 
A25-35 enhanced Tau phosphorylation (Lahmy et al., 2013; Zussy et al., 2013) by activating 
involved kinases such as GSK-3 (Lahmy et al., 2013). After determining the effective dose 
of L41, we observed that L41 prevented A25-35-induced cognitive impairments, spatial and 
non-spatial, short- and long-term memories in different behavioral tests. The neuroprotective 
effect of L41 was established for the dose of 4 µg by analyzing the oxidative stress (lipid 
peroxidation, reactive oxygen species), Tau phosphorylation and activation of kinases (AKT, 
GSK-3) involved in this process, expression of apoptosis markers (Bax, Bcl2), and synaptic 
markers (PSD95, Synaptophysin, Arc and Egr1). 
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2. Experimental procedures 
 
2.1. Animals 
Male Swiss mice (Depré, St-Doulchard, France), aged 7 weeks and weighing 32 ± 2 g, were 
used in this study. Animals, housed in groups had free access to food and water and were 
kept in a regulated environment (22 ± 1 °C, 40–60% humidity, 12 h light/dark cycle with light 
on at 07:00 h). Experiments were carried out between 09:00 and 17:00. All animal 
procedures were conducted in adherence to the European Union Directive of September 22, 
2010 (2010/63/UE). 
 
2.2. Drugs and administration procedures 
The amyloid-[25-35] (A25-35) and scrambled A25-35 (Sc.A) peptides were purchased from 
Genepep (Saint-Jean-de-Védas, France). They were solubilized in distilled water at 3 mg/ml 
and stored at -20°C. Peptides were incubated at 37°C for 4 days, allowing A25-35, but not 
Sc.A, to form oligomers (Zussy et al., 2013). They were administered i.c.v. as previously 
described in a final volume of 3 µl per mouse (Maurice et al., 1996; Haley and McCormick 
(1957). Injection coordinates from Bregma were: AP −0.4 mm, L 1.00 mm, V -2.50 mm 
(Paxinos and Franklin, 2012). The site of injection was confirmed a priori by indian ink in 
control animals. Leucettine L41, a potent inhibitor of DYRK and CLK kinases acting 
preferentially on DYRK1A, was produced as previously described (Debdab et al., 2011; 
Tahtouh et al., 2012; Burgy et al., 2013) and solubilized in dimethylsulfoxide (DMSO), 10% in 
final dilution (Sigma-Aldrich, St Quentin-Fallavier, France). L41 or vehicle was co-
administered i.c.v. (1 µl per mouse) at different doses: 0.4, 1.2 and 4 µg, corresponding 
respectively to 1.3, 3.9 and 13 nmol. These doses have been chosen to favor a specific 
action of L41 on DYRK1A, considering the protein kinase selectivity of L41: DYRK1A (IC50 = 
10-60 nM), DYRK1B (IC50 = 44 nM), DYRK2 (IC50 = 73 nM), DYRK3 (IC50 = 320 nM), DYRK4 
(IC50 = 520 nM), CLK1 (IC50 = 71 nM), CLK4 (IC50 = 64 nM) and GSK-3/ (IC50 =210-410 
nM). At the dose we used (4 µg, 13 nmol), the L41 would be active preferentially on the 
DYRK1A kinase. 
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2.3. Spontaneous alternation performances 
Each mouse was allowed to freely explore a Y-maze (three arms, 50 cm long, 60° separate)  
during a single 8-min session (Maurice et al., 1996). An alternation was defined as entries 
into all three arms on consecutive trials. The percentage of alternation was calculated as: 
actual alternations / total possible alternations x 100.  
 
2.4. Step-through passive avoidance test 
Each mouse was placed into the white compartment of a two-compartment apparatus. After 
5 s, the guillotine door was raised. When the mouse entered the darkened compartment, a 
scrambled footshock was delivered through the gridfloor (s (0.3 mA for 3 s; Lafayette 
Instruments, Lafayette, MA, USA). The step-through latency and sensitivity to the shock were 
recorded. The latter was evaluated as: 0 = no sign; 1 = flinching reactions; 2 = flinching and 
vocalization reactions. None of the treatments used in the present study affected latency or 
shock sensitivity during training (not shown). 24 h after training, each mouse was placed 
again into the white compartment. The step-through and escape latencies, i.e., the latency to 
re-exit from the dark compartment, were recorded up to 300 s.  
 
2.5. Place learning in the water maze 
The water-maze was a circular pool (diameter 140 cm, height 40 cm). Water temperature, 23 
± 1°C, light intensity, external cues in the room, and water opacity were unchanged. A 
transparent Plexiglas platform (diameter 10 cm) was immersed under the water surface. 
Swimming was recorded using the Videotrack® software (Viewpoint, Champagne-au-Mont-
d’Or, France), with trajectories being analyzed as latencies and distances. The software 
divides the pool into four quadrants. 
 Acquisition: between days 7 to 11 after peptide injection, training consisted in 3 swims 
per day, with 20 min intertrial time interval. Start positions, at limits between quadrants, were 
randomly selected and mice were allowed up to 90 s swim to find the platform. Animals were 
left on the platform during 20 s. The median latency was calculated for each training day. 
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 Retention: a probe test was performed after 24 h. The platform was removed and 
each animal was allowed a free 60 s swim. The time spent in the training (T) quadrant was 
analyzed. 
 
2.6. Lipid peroxidation measures 
Mice were killed by decapitation and brains rapidly dissected out, weighed and stored in 
liquid nitrogen. Hippocampi were homogenized in cold methanol (1/10, w/v), centrifuged at 
1,000 g during 5 min and supernatant collected. Homogenate was added to a solution 
containing FeSO4 1 mM, H2SO4 0.25 M, xylenol orange 1 mM, and incubated for 30 min at 
room temperature. Absorbance was measured at 580 nm (A5801), and 10 µl of cumene 
hydroperoxide (CHP) 1 mM was added and the sample incubated for 30 min at room 
temperature, to determine the maximal oxidation level. Absorbance was measured at 580 nm 
(A5802). The lipid peroxidation level was determined as CHP equivalents according to: CHP 
equiv. = A5801/A5802 x (CHP (nmol)) x dilution. 
 
2.7. Measurement of reactive oxygen species (ROS) 
ROS accumulation was determined by analyzing 2’,7’-dichlorofluorescein (DCF) 
fluorescence. DCF diacetate (0.5 µM) (Sigma-Aldrich) was applied to the hippocampus 
extract. DCF diacetate was readily converted into DCF, able to interact with peroxides 
(primarily H2O2) to form fluorescent DCF. DCF fluorescence was quantified (excitation 485 
nm, emission 530 nm) using a Fluoroskan Ascent spectrofluorimeter (Thermo Scientific, 
Waltham, USA), normalized for protein concentration. 
 
2.8. Western blotting 
Mice were decapitated 1, 3, 5 and 7 days after A25-35 peptide injection. Hippocampi were 
removed on ice-cold glass plate and stored at -80°C. Hippocampal tissues were 
homogenized by sonication in a lysis buffer (125 mM Tris-HCl pH 6.8, 4% SDS, 20% 
glycerol) including a protease and phosphatase inhibitors cocktail (Roche Diagnostics, 
Germany). Homogenates were heated at 70°C for 10 min and centrifuged at 16,000 g for 30 
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min at 4°C. Protein concentration was determined using a BCA assay (Pierce Biotechnology, 
Rockford, USA). Proteins, 20–40 µg per lane, were resolved on a 12% sodium 
dodecylsulfate-polyacrylamide gel and then transferred electrophoretically to a polyvinylidene 
difluoride membrane (GE Healthcare, France). After 1 h blocking in 5% non-fat dry milk in a 
20 mM Tris-buffered saline, pH 7.5, buffer containing 0.1% Tween-20, membranes were 
incubated overnight at 4°C with the primary antibodies (Table 1). After brief washes, 
membranes were incubated for 1 h at room temperature with corresponding secondary 
antibody (Table 1). The immunoreactive bands, visualized using enhanced 
chemiluminescence reagent (Pierce Biotechnology) were quantified using a quantitative 
fluorescence imaging system (Odyssey Fc, Li-Cor ScienceTec, France). Results were 
corrected with the corresponding -tubulin (-tub) level.  
 
2.9. Synaptic marker measures 
Hippocampi were homogenized in cold PBS. The content in synaptic markers —Arc, Egr1, 
PSD-95 and synaptophysin— were analyzed using ELISA kits (USCN Life Science, 
Euromedex, Souffelweyersheim, France). Levels in synaptic markers were expressed as 
ng/mg hippocampus wet weight. 
 
2.10. Experimental series 
As schematized in Figure 1, the first experimental series address the dose-response effect of 
L41 in A25-35-treated mice. L41 was injected at the doses of 0.4, 1.2, 4 µg/mouse i.c.v. and 
animals were tested in the spontaneous alternation and passive avoidance tests. After 
retention, animals were sacrificed, their brain dissected out and their hippocampus used for 
lipid peroxidation measures. In the second experimental series, animals were treated with 
L41 at the most active dose, i.e., 4 µg/mouse, and used for place learning in the water-maze, 
and biochemical analyses (DCF, kinase activity, Tau phosphorylation and synaptic markers). 
For the latter, the Sc.A/L41-treated group was added as a drug-alone control group.   
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2.11. Statistical analyses 
Biochemical and behavioral data were expressed as mean ± SEM, except step-down 
latencies expressed as median and interquartile range. They were analyzed using one-way 
ANOVA (F values), followed by the Dunnett’s post hoc multiple comparison test. Passive 
avoidance latencies, expressed as median and interquartile (25%-75%) range, were 
analyzed a Kruskal-Wallis nonparametric ANOVA (H values), as upper cut-off times were 
set, followed by the Dunn’s multiple comparison test. Acquisition profiles in the water-maze 
were analyzed using the non-parametric repeated-measure Friedman's ANOVA (Fr value), 
followed by a Mann-Whitney's test for post-hoc comparisons. Probe test data were presented 
as time spent in the quadrants. Presence in the T quadrant was analyzed using a one-
sample t-test vs. the chance level (15 s). The level of statistical significance was p < 0.05. 
 
 
3. Results 
 
 3.1. The Leucettine L41 prevented A25-35-induced spatial and non-spatial, short- and 
long-term memory impairments 
To determine whether L41 possessed neuroprotective properties, we co-administered L41 
with A25-35, in the 0.4-4 µg dose-range. The spatial working memory was assessed using 
spontaneous alternation in the Y-maze (Fig. 2a,b). The deficits observed in mice treated with 
A25-35 were dose-dependently and significantly prevented in mice co-administered with L41, 
particularly at the doses of 1.2 and 4 µg (Fig. 2a). In parallel, none of the treatments affected 
the locomotor and exploratory responses, measured in terms of number of arms entries (Fig. 
2b). Non-spatial long-term memory was assessed using the passive avoidance procedure 
(Fig. 2c,d). None of the treatments affected the step-through latency and sensitivity to the 
shocks, during the training session (data not shown). During the retention session, the A25-35 
treatment provoked a significant decrease in step-through latency (Fig. 2c) and an increase 
in escape latency (Fig. 2d) (t test p = 0.065 vs. Sc.A V). L41 co-administration prevented 
the A25-35-induced deficits, a significant effect being measured at the dose of 4 µg for the 
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step-through latency (Fig. 2c).  
The efficacy of L41 (4 µg) was analyzed on long-term spatial memory using place 
learning in the water-maze (Fig. 3). Analyses of acquisition profiles showed that the latencies 
measured for the Sc.A/V-treated group significantly decreased over training trials (Fig. 3a). 
By contrast, A25-35 failed to show any significant decrease in latency indicating an 
impairment of memory acquisition (Fig. 3a). Indeed, latencies measured during trials 4 and 6 
were significantly higher than those measured for the Sc.A/V control group. The L41 co-
administration restored learning capacity, as shown by the significant decrease in swimming 
duration, with significant differences measured from trial 3 to trial 6 as compared to A25-35/V-
treated animals (Fig. 3b). Analysis of the animal presence in the training (T) quadrant of the 
pool during the probe test showed that Sc.A/V-treated animals spent significantly more time 
in this quadrant than hazard level (15 s), confirming an effective learning of the platform 
location (Fig. 3c). The presence of the A25-35/V-treated group remained non-significantly 
different from the hazard level, indicating a failure to acquire the platform location (Fig. 3c). 
L41 co-administration significantly prevented the deficit (Fig. 3c). To note, none of the 
treatment altered the swimming speed of the animals during the probe test session (Fig. 3d). 
 
3.2. L41 decreased A25-35-induced oxidative stress in mice hippocampus 
To assess the effect of A25-35 on oxidative stress in the mouse hippocampus, we measured 
the level of lipid peroxidation 1, 3, 5 and 7 days after the icv injection of the peptide. A25-35 
significantly increased lipid peroxidation, 5 and 7 days after injection (Fig. 4a). L41, at 4 µg, 
prevented significantly the A25-35-induced increase in lipid peroxidation level (Fig. 4b). A 
second assay of oxidative stress in mice hippocampus was performed by an indirect 
quantification of ROS accumulation using the measurement of DCF fluorescence. It was 
significantly increased 7 days after A25-35 injection (Fig. 4c). L41, at the dose of 4 µg, 
abolished the A25-35-induced increase in DCF fluorescence (Fig. 4d). To note L41 alone had 
no effect on DCF fluorescence (Fig. 4d). 
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3.3. L41 blocked A25-35-induced GSK-3 activation and Tau phosphorylation in mice 
hippocampus 
In order to analyze the effect of L41, injected at 4 µg/mouse, on GSK-3 activation in 
hippocampus, we determined the level of phosphorylation on Ser473 for Akt, and Tyr216 and 
Ser9 for GSK-3 (Fig. 5). Indeed, P(Ser473)Akt is an indirect measure of Akt activity, which is 
responsible notably for Ser9 phosphorylation on GSK-3, which inactivates the kinase. 
Phosphorylation on Tyr216 is on the contrary linked to GSK-3 activation. A25-35 injection 
rapidly and transiently decreased P(Ser473)Akt/Akt ratio (Fig. 5a). Co-administration of L41 
partially but significantly prevented the decrease in P(Ser473)Akt/Akt ratio, 1 day after i.c.v. 
injections (Fig. 5b). Rapidly and long-lastingly until 7 days after A25-35 injection, the 
P(Tyr216)GSK-3/GSK-3 ratio was significantly increased in mouse hippocampus (Fig. 5c), 
whereas P(Ser9)GSK-3/GSK-3 ratio was transiently decreased at day 3 (Fig. 5e). L41 
prevented the A25-35-induced increase in P(Tyr216)GSK-3/GSK-3 ratio, 7 days after i.c.v. 
injections (Fig. 5d). The DYRK1A preferential inhibitor also significantly decreased the basal 
level of P(Tyr216)GSK-3 (Fig. 5d). In addition, L41 also prevented the decrease in 
P(Ser9)GSK-3/GSK-3 ratio, on day 3 (Fig. 5f). Here again, the basal level of P(Ser9)GSK-
3 was decreased by L41 (Fig. 5f). 
In summary, A25-35 induced a global increase of GSK-3 activity, as revealed by 
decreased P(Ser473)Akt/Akt ratio (decreased Akt activity) and both decreased P(Ser9)GSK-
3/GSK-3 ratio and increased P(Tyr216)GSK-3/GSK-3 ratio. This A25-35-induced increase 
of GSK-3 activity was prevented by L41. 
In addition, A25-35 provoked a robust increase of Tau phosphorylation on 
Ser202/Thr205, a physiological epitope recognized by the AT8 antibody (Fig. 6a, c). A25-35 
showed only a tendency to increase Tau phosphorylation on Thr212/Ser214 (+41%, ns), a 
pathological epitope recognized by the AT100 antibody (Fig. 6b, c). L41 partially, but 
significantly, prevented the A25-35-induced Tau phosphorylation on Ser202/Thr205 (Fig. 6a, c). 
The DYRK1A inhibitor had only a marginal effect on Tau phosphorylation on Thr212/Ser214 
(Fig. 6b, c).  
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3.4. L41 prevented A25-35-induced pro-apoptotic pathways and disrupted synaptic 
integrity 
The protective properties of L41, injected at 4 µg/mouse, on neuronal integrity were also 
analyzed. A25-35 triggered activation of the apoptotic pathway (Fig. 7). Indeed, time-course 
analysis of the expression of the pro-apoptotic protein Bax revealed a sustained increase in 
the hippocampus after A25-35 injection (Fig. 7a). The highest level was observed 7 days after 
A25-35 injection. The co-administration of L41 prevented this increase of Bax expression (Fig. 
7b). In addition, 7 days after
 
injection, A25-35 induced a significant decrease in the expression 
of the anti-apoptotic protein Bcl-2 (Fig. 7c). L41 is prevented the A25-35-induced decrease in 
Bcl-2 (Fig. 7c). As Bax and Bcl-2 can form heterodimers, determination of the Bax/Bcl-2 ratio 
is highly relevant. The Bax/Bcl-2 ratio was calculated for each animal of the different groups. 
It appeared robustly increased after A25-35 injection (Fig. 7d), while L41 fully prevented this 
increase (Fig. 7d). 
In addition, the level of pro-caspase 9 was also determined in the hippocampus. A25-
35 induced, 7 days after injection, a significant increase in pro-caspase 9 expression (Fig. 7e). 
L41 prevented the increase in pro-caspase 9 expression triggered by A25-35 (Fig. 7e). 
The synaptic integrity was assessed in the mouse hippocampus by determining the 
level of several synaptic markers, 7 days after
 
injection. The levels of Arc, Egr1, PSD95 and 
synaptophysin were significantly lowered in A25-35 treated mice by -25%, -18%, -54% and -
19%, respectively (Fig. 8a-d). The co-administration of L41 prevented the A25-35-induced 
decrease of Arc, PSD95 and synaptophysin levels (Fig. 8a,c,d). A marginal effect was 
measured on Egr1 expression. To note, L41 had no effect on these parameters in Sc.A-
treated animals.  
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4. Discussion 
 
Kinases are major players in the etiology and progression of AD. However, to date, the most 
studied kinases, GSK-3 and CDK5, revealed poor therapeutic potentials. We here analyzed 
the implication of a less investigated kinase, DYRK1A, in an animal model of A toxicity. Our 
results highlighted for the first time a role of DYRK1A in amyloid toxicity and suggested that 
DYRK1A inhibitors could be promising new therapeutic compounds for AD.  
We used the acute model of A toxicity where A25-35 i.c.v. injection provoked rapidly 
and sustainably an AD-like toxicity and learning and memory impairments (Maurice et al., 
1996; Kaminsky et al., 2010; Zussy et al., 2011). Seven days after injection, A25-35-treated 
mice exhibited deficits in spontaneous alternation, passive avoidance response and spatial 
learning in the water-maze. We demonstrated that L41 was able to prevent the onset of 
these cognitive impairments when the drug was co-administered with A25-35. Similarly to 
harmine, L41 is an inhibitor of DYRKs and CLKs, two related families of kinases, some 
members of which are involved in the onset and development of AD and DS, and acting 
preferentially on DYRK1A. L41 and harmine showed consistently similar inhibition rates for 
DYRK1A and CLK1. L41 displays neuroprotective properties in vitro (Tahtouh et al., 2012). 
Indeed, it provoked a dose-dependent inhibition of the neurodegeneration induced by APP in 
cultured cells, with a more robust effect than harmine. In addition, a specific knockdown of 
DYRK1A expression by siRNA inhibited neurodegeneration induced by APP (Tahtouh et al., 
2012), suggesting a major role of DYRK1A in APP-induced neurotoxicity. These in vitro 
studies revealed that the pharmacological or genetic inhibition of DYRK1A activity seems to 
be a promising approach to counteract A-induced neurodegeneration. In addition, harmine, 
used as the same doses as L41, induced neuroprotective effects in mice brain when co-
administered i.c.v. with A25-35, but to a lesser extend than L41 (unpublished data), 
suggesting that L41 would be a better pharmacological tool. 
As observed in AD, we have previously shown an increase of GSK-3 activity in the 
A25-35 mouse model (Lahmy et al., 2013). This result confirms previous data demonstrating 
A25-35-induced GSK-3 activity in primary cultures of hippocampic neurons (Takashima et 
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al., 1998). Here, we have clearly shown that L41 inhibited the A25-35-induced GSK-3 
activity in mice hippocampus. This L41 effect on GSK-3 could occur by both direct and 
indirect mechanisms. In vitro studies showed that L41 interacts both with DYRK1A and GSK-
3 and reduced their activity (Tahtouh et al., 2012; Burgy et al., 2013). Among all L41 kinase 
targets enriched from mouse brain, DYRK1A and GSK-3 are the two kinases interacting with 
L41 identified by affinity chromatography approaches (Tahtouh et al., 2012). However, L41 
treatment (0.01 to 10 µM) of mouse hippocampal cell lines did not affect GSK-3 activity, but 
reduced robustly DYRK1A activity (Tahtouh et al., 2012). Although the dose used in this 
culture experiment is 1000 time higher than the one used in our study (13 nmol), L41 failed to 
affect GSK-3 activity. Therefore, the decreased activity of GSK-3 observed in our study 
could not result from a direct action of L41 on GSK-3. Accordingly, GSK-3 activity could be 
modulated by L41 effect on other kinases regulating GSK-3. Indeed, its activity depends on 
phosphorylation at specific sites. Ser9 phosphorylation is related to inhibition of GSK-3 
activity, whereas phosphorylation on its Tyr216 results in activation (Medina et al., 2011). 
Many protein kinases, including Akt, are competent at phosphorylating GSK-3 on Ser9 
(Fang et al., 2000; Medina et al., 2011). Once activated, as revealed by its phosphorylation 
on Ser473, Akt phosphorylates GSK-3 on its inhibitory residue, Ser9 (Fang et al., 2000). 
Although A25-35 inhibited Akt activity, L41 was able to prevent this Akt inhibition. This L41 
effect on Akt would certainly contribute to the inhibition of GSK-3 activity. In addition, L41 
interacts predominantly with DYRK1A, which acts as a priming kinase. Indeed, DYRK1A 
phosphorylates Tau on different residues enhancing then it phosphorylation by other kinases 
on distinct sites (Woods et al., 2001). Therefore, L41 could also affect GSK-3 activity by a 
reduction of these priming effects. In addition, L41 could also affect GSK-3 activity by an 
indirect effect, as previously described for other kinase inhibitors. Indeed, CDK5 inhibitor 
increased GSK-3 activity by a CDK5-mediated direct modulation of phosphatases inducing 
Ser9 dephosphorylation (Morfini et al., 2004). Although such effect has not yet been reported 
for DYRK1A, we cannot exclude that L41 can affect phosphatase activity. Therefore, the 
decrease of Tau phosphorylation induced by L41 could be explained by a decreased activity 
of kinases involved in this process, such as GSK-3 and DYRK1A, but also by a reduction of 
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the priming function of DYRK1A. More in details, A25-35 increased Tau phosphorylation at 
Ser202 and Thr205, but had no effect on it phosphorylation at Thr212 and Ser214. L41 had no 
effect on these different phosphorylations in basal conditions, i.e., in Sc.A/L41-treated 
animals. By contrast, L41 is able to prevent partially the A25-35 induced increase of Tau 
phosphorylation at Ser202 and Thr205, suggesting that other kinases are involved. The lack of 
L41 effect on Tau phosphorylation at Thr212 and Ser214 could be explained by the absence of 
A25-35 effect. Despite the ability of DYRK1A to phosphorylate Tau at Thr212 (Woods et al., 
2001; Liu et al., 2008), some discrepancy on the role of DYRK1A in Thr212 phosphorylation 
has been reported in the literature. Depending on the transgenic mice model overexpressing 
DYRK1A and the mouse age, Thr212 phosphorylation can involve DYRK1A activity (Ferrer et 
al., 2005; Liu et al., 2008; Sheppard et al., 2012). Furthermore, DYRK1A-mediated Tau 
phosphorylation primed further phosphorylation at Ser199, Ser202, Thr205 and Ser208 by GSK-
3 (Woods et al., 2001; Liu et al., 2008), suggesting a general role for DYRK1A in Tau 
phosphorylation. In our model, DYRK1A seems not to affect Tau phosphorylation at Thr212 
and, thus would not prime Tau phosphorylation by GSK-3. Then, L41, having no effect on 
Thr212 phosphorylation, would not affect Tau phosphorylation by GSK-3 through the 
DYRK1A priming activity. 
A well-characterized hallmark of A toxicity is oxidative stress. In the A25-35 model, 
lipid peroxidation and ROS accumulation were increased and the co-administration of L41 
prevented this A25-35-induced oxidative stress. Therefore, L41 exhibited antioxidant 
properties, as observed for other DYRK1A preferential inhibitors the EGCG (Mandel et al., 
2008) and harmine (Reus et al., 2010). Moreover A25-35 injection also induced pro-apoptotic 
pathways as revealed by the rapid and sustained increase of Bax protein expression. At the 
same time, the expression of an anti-apoptotic protein, Bcl-2, is greatly decreased. These 
results are consistent with altered expression levels of Bcl-2 family proteins observed in AD 
(Kitamura et al., 1998). Concomitantly, A25-35 enhanced the level of pro-caspase 9. L41 is 
able to prevent this A25-35-induced pro-apoptotic pathway and pro-caspase expression. This 
L41 effects are of great interest and suggest the involvement of DYRKs/CLKs and 
particularly DYRK1A in this A25-35-induced pro-apoptotic pathways. One explanation is that 
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DYRK1A regulates pro-apoptotic pathways through regulation of GSK-3 activity. Indeed, a 
recent in vitro study highlighted that GSK-3 is able to directly enhance Bax activity in neuron 
cells (Ngok-Ngam et al., 2013). In addition, previous studies demonstrated that fibrillar and 
oligomeric A induced cell death through a Bax-dependent mechanism (Giovanni et al., 
2000; Kudo et al., 2012). However, it remains unknown how oligomeric or fibrillar A 
activates Bax, one potential pathway being kinase activation. Indeed, A is known to activate 
c-Jun N-terminal kinase (JNK). CDK kinases, more particularly CDK4, seem also to be 
involved in this A-induced apoptotic pathway (Giovanni et al., 2000). Here, we 
demonstrated that a DYRK1A-preferential inhibitor prevented the induction of pro-apoptotic 
pathways. This effect could be explained by a coupling of DYRK1A to JNK1 activation, 
directly interacting with apoptosis signal regulating kinase 1 (ASK1). Moreover, DYRK1A 
positively regulates ASK1-mediated JNK1-signaling, and appears to directly phosphorylate 
ASK1 (Choi and Chung, 2011). Therefore, DYRK1A is able to modulate apoptotic markers 
expression and activity and plays a key role in ASK1-mediated transmission of cell death 
signals. 
The first signs of AD occur with subtle alterations in the hippocampal synaptic activity 
prior to frank neuronal degeneration (Selkoe, 2002). Soluble A species may affect synaptic 
functions since it abrogates synaptic plasticity, induces memory impairments and interferes 
with normal activity and trafficking of several synaptic receptors (Ma and Klann, 2011). 
Moreover the expression of genes critical for memory or neuroprotection in hippocampus is 
affected by A (Dickey et al., 2004) and both intra- and extracellular A has the ability to 
affect their expression (Wegenast-Braun et al., 2009). This gene expression reduction have 
been previously described in APPSwe/PS1 mice and occurred concomitantly with onset of the 
cognitive decline (Naert and Rivest, 2012). Here, A25-35 induced a decrease expression of 
Arc, Egr1, PSD95 and synaptophysin, concomitantly with learning and memory impairments, 
and both synaptic marker reduction and memory deficit can be prevented by the co-
administration of L41. The immediate early genes Arc and Egr1 are clearly involved in 
learning and memory processes in hippocampus. The postsynaptic density protein-95 (PSD-
95) is a molecule critical for synaptic plasticity (Malinow and Malenka, 2002). This deficit in 
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synaptic markers could explain, at least in part, the A25-35-induced memory and learning 
impairments. Indeed, the occurrence of cognitive impairment is correlated with a decline in 
Arc and Egr1 expression levels during aging (Blalock et al., 2003) and in AD transgenic mice 
model (Dickey et al., 2004; Naert and Rivest, 2012). PSD-95 is involved in recruiting and 
holding glutamate receptors at the surface (Xiao et al., 1998) and Arc expression is also 
closely related to N-methyl-D-aspartate (NMDA) receptor activity (Bloomer et al., 2008). 
Down-regulation of these genes clearly affects synaptic plasticity processes underlying long-
term potentiation and memory in AD.  
In conclusion, this in vivo study reveals for the first time the major role of DYRK1A in 
A toxicity. Although the pharmacological inhibitor Leucettine 41 targets DYRKs/CLKs, L41 
effects on A toxicity seem to be attributed to inhibition of DYRK1A in particular, as DYRK1A 
is the main target of L41 in mouse brain. Due to DYRK1A involvement in Tau 
hyperphosphorylation, its role in A toxicity validates DYRK1A as key kinase of AD. 
Targeting DYRK1A in a therapeutic strategy would permit to act on the two major component 
of AD, Tau hyperphosphorylation and A pathology. Thus, the Leucettine L41, and the other 
members of the Leucettine family, constitutes promising therapeutic compounds to 
counteract the development and the progression of AD. 
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Table 1 Antibodies used in Western blot experiments 
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Figure legends 
 
Figure 1 Experimental protocol. Abbreviations: ICV, intracerebroventricular injection; 
YMT, Y-maze test; ST-PA, step-through passive avoidance; Sacrf., sacrifice of the animals 
and brain dissection; WMT, wtater-maze test; LPO, lipid peroxidation; DCF, ROS 
determination by DCF fluorescence. 
 
Figure 2 L41 prevented spatial working and contextual long-term memory impairments 
induced by A25-35 injection. Mice were administered i.c.v. with Sc.A or A25-35 peptide (9 
nmol) and vehicle or L41 (0.4, 1.2, or 4 µg/mouse). At day 7, they were tested for 
spontaneous alternation: alternation percentage (a) and number of arm entries (b). At days 
8-9, mice were tested for passive avoidance response: step-through latency (c) and escape 
latency (d). n = 16-17 per group. ANOVA: F(4,79) = 6.29, p < 0.001 in (a), F(4,79) = 0.42, p > 
0.05 in (b); H = 15.0, p < 0.01 in (c); H = 5.12, p < 0.05 in (d). * p < 0.05; ** p < 0.01 vs. 
Sc.A/V; # p < 0.05; ## p < 0.01 vs. A25-35/V; Dunnett's test in (a), Dunn's test in (c, d). 
 
Figure 3 L41 prevented A25-35-induced learning impairments in the water-maze test. 
Mice were administered i.c.v. with Sc.A or A25-35 peptide (9 nmol) and vehicle or L41 (4 
µg). Place learning was assessed after 7 days: acquisition profiles (a, b) and the time spent 
in the T quadrant (c) and swimming speed (d) during the probe test. n = 12 per group. 
Repeated-measure non-parametric Friedman ANOVA: Fr = 23.6, p < 0.001 for Sc.A/V-
treated group; Fr = 10.6, p > 0.05 for A235-35/V-treated group in (a); Fr = 24.7, p < 0.001 for 
A235-35/L41-treated group in (b); F(2,35) = 1.23, p > 0.05 in (d). ** p < 0.01 vs. Sc.A/V at the 
same trial; # p < 0.05; ## p < 0.01 vs. A25-35/V at the same trial; Mann-Whitney's test in (a, 
b). * p < 0.05; ** p < 0.01 vs. hazard level (15 s), one-column t-test in (c). 
 
Figure 4 L41 prevented A25-35-induced oxidative stress in hippocampus. Oxidative 
stress was assessed 1, 3, 5 and 7 days after A25-35 injection in mouse hippocampus by 
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measuring lipid peroxidation (a) and ROS accumulation using DCF fluorescence (c). The 
effect of L41, at the dose of 4 µg, on A25-35-induced lipid peroxidation (b) and ROS 
accumulation (DCF) (d) was then assessed in the mouse hippocampus 7 days after co-
injection. ** p < 0.01, *** p < 0.001 vs. Sc.A control group on the same day; t-test, n = 6 per 
group in (a), n = 4-5 in (c). ANOVA: F(3,20) = 4.79, p < 0.05, n = 6 per group in (b); F(3,32) = 
4.10, p < 0.05 n = 8-10  in (d); * p < 0.05 vs. Sc.A/V-treated group; ## p < 0.01 vs. A25-35/V-
treated group, Dunnett’s test. 
 
Figure 5 L41 prevents A25-35-induced activation of kinases involved in Tau 
phosphorylation. Mice were administered i.c.v. with Sc.A or A25-35 peptide and sacrificed 1, 
3, 5, 7 days after injection. The time-course of phosphorylation was determined for Akt on 
Ser473 (a) and GSK-3 on Tyr216 (c) and Ser9 (e) in the hippocampus of A25-35-treated mice. 
The effect of L41, 4 µg, was then examined on A25-35-induced decrease in P(Ser473)Akt/Akt 
ratio at day 1 (b), p(Tyr216)GSK-3/GSK-3 ratio at day 7 (d) and P(Ser9)GSK-3/GSK-3 at 
day 3 (f). Typical blots are shown under the graphs; the order of the experimental group is 
the same as described for the graph. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. Sc.A control 
group on the same day; t-test, n = 8-14 per group in (a), n = 9-14 in (c), n = 6-8 in (e). 
ANOVA: F(2,33) = 18.3, p < 0.0001, n = 11-13 per group in (b); F(3,38) = 10.75, p < 0.0001, n = 
4-14  in (d); F(3,23) = 1.90, p > 0.05, n = 5-8 in (f); * p < 0.05, ** p < 0.01, *** p < 0.001 vs. 
Sc.A/V-treated group; # p < 0.05, ## p < 0.01 vs. A25-35/V-treated group, Dunnett’s test. 
 
Figure 6 L41 prevented the A25-35-induced phosphorylation of Tau. Mice were 
administered i.c.v. with Sc.A or A25-35 peptide and L41 (4 µg) and sacrificed 7 days after 
injection. Tau phosphorylation was assessed by western blotting using AT8 (Ser202/Thr205) (a) 
and AT100 (Ser212/Thr214) antibodies (b). Typical blots are shown in (c). ANOVA: F(3,39) = 
17.6, p < 0.001, n = 10-12 in (a); F(3,66) = 1.07, p > 0.05, n = 15-20, in (b); * p < 0.05, ** p < 
0.01 vs. Sc.A/V-treated group; # p < 0.05 vs. A25-35/V-treated group; Dunnett’s test. 
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Figure 7 L41 prevented A25-35 induction of pro-apoptotic pathway. Mice were 
administered i.c.v. with Sc.A or A25-35 peptide (9 nmol) and sacrificed 1, 3, 5 and 7 days 
after injection. The level of Bax expression was assessed by western blot in hippocampus 
(a). The effect of L41 (4 µg) on A25-35-induction of pro-apoptotic markers was examined in 
the mouse hippocampus 7 days after co-injection: Bax (b), Bcl-2 (c), Bax/Bcl-2 ratio (d) and 
pro-caspase-9 (e). Typical blots are shown in (f, g). * p < 0.05 vs. Sc.A control group on the 
same day; t-test, n = 6-8 per group in (a). ANOVA: F(3,21) = 4.81, p < 0.01, n = 6-7 in (b); F(3,42) 
= 2.87, p < 0.05, n = 8-15 in (c); F(3,44) = 5.46, p < 0.01, n = 11-13 in (d); F(3,41) = 3.72, p < 
0.05, n = 11 -12 in (e); * p < 0.05, ** p < 0.01 vs. Sc.A/V-treated group; # p < 0.05 vs. A25-
35/V-treated group; Dunnett’s test. 
 
Figure 8 L41 reverses synaptic markers deficit in the hippocampus induced by A25-35 
injection. Mice were administered i.c.v. with Sc.A or A25-35 peptide (9 nmol) and L41 (4 µg) 
and sacrificed 7 days after injection. The levels of synaptic markers were assessed in 
hippocampus by ELISA: Arc (a), Egr1 (b), PSD95 (c) and synaptophysin (d). ANOVA: F(3,28) = 
3.61, p < 0.05, n =  6-9 in (a); F(3,30) = 3.00, p < 0.05, n = 8-10 in (b); F(3,28) = 3.71, p < 0.05, n 
= 6-10, in (c); F(3,28) = 3.59, p < 0.05, n = 7-9 in (d); * p < 0.05 vs. Sc.A/V-treated group; # p 
< 0.05 vs. A25-35/V-treated group; Dunnett’s test. 
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